Page 3 - Sanofi India

Sanofi posts stronger-than-expected result in Q4, eyes more cost cuts

The French company, which stunned investors last year with the delay of a COVID-19 vaccine candidate, confirmed an operating income margin target of 30%

Sanofi India: Long-term investors advised to consider the stock on dips

Analysts see 19 per cent annual growth in earnings during FY20-22 with significant rise in return ratios post sale of a facility

Sanofi and GSK launch trial for protein-based coronavirus vaccine

PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments

Sanofi more confident about its coronavirus vaccines, trials next month

The company is working on two of the more than 150 potential vaccines being developed across the world to tackle the Covid-19 pandemic

Sanofi India gains 5%, hits 52-week high; stock soars 8% so far in August

Early this week, the comany's parent firm Sanofi said it will acquire all of the outstanding shares of US-based Principia Biopharma Inc. for a total approximate aggregate equity value of $3.68 billion

Next target for Nifty is seen at 11,550: Vinay Rajani of HDFC Securities

Traders are advised to hold Nifty longs with 11,200 stoploss and keep it trailing as Nifty rises

French group Sanofi to buy US firm Principia Biopharma for $3.7 billion

PARIS (Reuters) - French healthcare company Sanofi SA has agreed to buy U.S. company Principia Biopharma Inc for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and development (R&D) areas.

Nifty outlook and stock pick by HDFC Sec: Buy UltraTech Cement, Sanofi

NIfty has been forming higher tops and higher bottoms on the daily charts. Nifty is placed above 20,50,100 and 200 days moving averages, indicating bullish trend on all time frames

Sanofi India: Sturdy balance sheet, cash-generation augur well for company

High growth visibility in chronics, strong balance sheet will help sustain premium valuation

Sanofi, GSK to supply up to 60 million doses of Covid-19 vaccine to UK

Sanofi and GSK said they had reached an agreement with Britain to supply it with up to 60 million doses of a potential Covid-19 vaccine, and that discussions with other governments were ongoing

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter

Sanofi stops enrolling Covid-19 patients in hydroxychloroquine trials

The moves come after the World Health Organization paused its large trial of hydroxychloroquine, prompting several European governments to ban the use of the drug

From Nestle India to Maruti Suzuki, impact of Covid-19 on earning estimates

Given the huge hit from lockdown, it is not surprising that 44 of the 80 companies have seen sharp cuts ranging 10% to 72%

Double whammy: Power brands give Sanofi revenues and an edge over peers

One-time dividend of Rs 243 has given a leg up to sentiment

Market Wrap, Feb 26: Sensex ends 392 pts lower, Nifty at 11,678

Among sectoral indices, Nifty Auto index slipped the most - over 2 per cent to 7,208 levels. Nifty Metal index dropped 1.63 per cent to 2,430

Sanofi India hits record high, surges 9% on dividend of Rs 349 per share

The total dividend of Rs 343 per share includes a one-time special dividend of Rs 243 per equity share for the year ended December 31, 2019.

Nordisk and Sanofi log double-digit revenue growth in insulin pens

Around 6.98 million insulin pens were sold; it was 6.97 mn in the year-before period

Sanofi to reward shareholders with Rs 261 cr made from Ankleshwar unit sale

The sale will translate into average annual revenue loss of Rs 470 cr, which Sanofi plans to mitigate through renewed focus on core activities and brands

Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain

Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers

Strong product mix, new launches to keep Sanofi India margins elevated

Street positive given attractive valuations; stock trading at 16x its CY20 estimates